Marathon Pharmaceuticals Treatment Pipeline and Pricing Concerns

Marathon Pharmaceuticals has been making headlines for its treatment pipeline and pricing concerns. The company acquired the rights to Lofgren's disease treatment, a rare genetic disorder, and raised its price from $375 to $89,000 per year.

The price hike sparked outrage among patients, advocates, and lawmakers. Marathon Pharmaceuticals claimed the price increase was necessary to recoup research and development costs.

Critics argue that the company's actions are predatory and take advantage of patients who have limited treatment options. Marathon Pharmaceuticals has a history of acquiring and rebranding existing treatments, increasing their prices significantly.

The company's business model has been criticized for prioritizing profits over patient needs.

Expand your knowledge: King Price Insurance

Marathon developed late-stage drugs and earned regulatory approvals, allowing them to manufacture and commercialize medicines with input from patient advocacy groups.

Their regulatory efforts focused on gaining FDA approval of New Drug Applications (NDA) or Biologic License Applications (BLA).

The company provided assistance for eligible patients with financial hardship, helping them secure other assistance through the National Organization of Rare Disorders (NORD) and similar patient support groups.

Marathon was criticized for using regulatory loopholes and FDA incentives to acquire drugs cheaply, then multiplying the list price to make a profit.

Marathon distributed its products in North America.

Marathon Pharmaceuticals has found itself at the center of a controversy surrounding the pricing of its new treatment for Duchenne muscular dystrophy (DMD).

The company priced Emflaza, a treatment for DMD, at $89,000 a year. This move sparked widespread criticism and led to a reevaluation of the pricing.

Congressional scrutiny of Marathon Pharmaceuticals grew last week, with a group of senators demanding answers on how much the company paid to develop Emflaza.

A letter from the eight senators expressed concern that Marathon's pricing unfairly exploits the DMD patient population and the FDA's orphan drug incentives.

Deflazacort, the active ingredient in Emflaza, was approved as a new drug under the Orphan Drug Act, granting Marathon seven years of marketing exclusivity.

This exclusivity is significant, as the old steroid has been used for years off-label to treat DMD.

You might like: Swedish Orphan Biovitrum

Marathon Pharmaceuticals has made significant contributions to the treatment of various disorders.

The company developed medications that target neurological, muscular, gastrointestinal, and blood disorders.

One notable medication is deflazacort, a treatment for Duchenne muscular dystrophy (DMD) that can slow the progression of the disease.

In January 2015, Marathon received fast track status from the FDA for deflazacort.

Deflazacort and Exondys 51 are the only FDA-approved drugs that treat DMD, as of 2/12/2017.